MNos2 deletion and human NOS2 replacement in alzheimer disease models

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 8, 2014, Pages 752-769

  Colton, Carol A ^a   Wilson, Joan G ^a   Everhart, Angela ^a   Wilcock, Donna M ^a,c   Puoliväli, Jukka ^b   Heikkinen, Taneli ^b   Oksman, Juho ^b   Jääskeläinen, Olli ^b   Lehtimäki, Kimmo ^b   Laitinen, Teemu ^b   Vartiainen, Nina ^b   Vitek, Michael P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Charles River Discovery Research Services Finland   (Finland)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease; Magnetic resonance spectroscopy; Mouse model; Neuronal loss; NOS2; Tau pathology

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MEMORY CONSOLIDATION; MNOS2 GENE; MOUSE; NONHUMAN; NOS2 GENE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPATIAL MEMORY;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION;

EID: 84904717148     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000094     Document Type: Article

References (112)

1. Schindler SE, McConathy J, Ances BM, et al. Advances in diagnostic testing for Alzheimer disease. Mo Med 2013;110:401-5
2. Teipel SJ, Grothe M, Lista S, et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am 2013;97:399-424
3. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimers Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2013;9:e111-94
4. Gama Sosa MA, De Gasperi R, Elder GA. Modeling human neurodegenerative diseases in transgenic systems. Hum Genet 2012;131:535-63
5. Kitazawa M, Medeiros R, Laferla FM. Transgenic mouse models of Alzheimer disease: Developing a better model as a tool for therapeutic interventions. Curr Pharm Des 2012;18:1131-47
6. Radde R, Duma C, Goedert M, et al. The value of incomplete mouse models of Alzheimers disease. Eur J Nucl Med Mol Imaging 2008; 35(Suppl 1):S70-74
7. Colton CA, Vitek MP, Wink DA, et al. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimers disease. Proc Natl Acad Sci U S A 2006;103:12867-72
8. Colton CA, Wilcock DM, Wink DA, et al. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis 2008;15:571-87
9. Wilcock DM, Lewis MR, Van Nostrand WE, et al. Progression of amyloid pathology to Alzheimers disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 2008;28:1537-45
10. Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 2004;279:20296-306
11. Attems J, Jellinger K, Thal DR, et al. Review: Sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011;37:75-93
12. Miao J, Vitek MP, Xu F, et al. Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammationin vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci 2005;25:6271-77
13. Miao J, Xu F, Davis J, et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol 2005;167:505-15
14. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimers disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-21
15. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004;172:2731-38
16. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118:1680-90
17. Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184-95
18. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimers disease. Cell 2013;153:707-20
19. Kamboh MI, Demirci FY, Wang X, et al. Genome-wide association study of Alzheimers disease. Transl Psychiatry 2012;2:e117
20. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013;110:3507-12
21. Vitek MP, Brown C, Xu Q, et al. Characterization of NO and cytokine production in immune-activated microglia and peritoneal macrophages derived from a mouse model expressing the human NOS2 gene on a mouse NOS2 knockout background. Antioxid Redox Signal 2006;8: 893-901
22. Laubach VE, Foley PL, Shockey KS, et al. Protective roles of nitric oxide and testosterone in endotoxemia: Evidence from NOS-2-deficient mice. Am J Physiol 1998;275:H2211-18
23. Carter-Dawson LD, LaVail MM. Rods and cones in the mouse retina. II. Autoradiographic analysis of cell generation using tritiated thymidine. J Comp Neurol 1979;188:263-72
24. Mattapallil MJ, Wawrousek EF, Chan CC, et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57Bl/6J mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci 2012;53:2921-27
25. Vitek MP, Snell J, Dawson H, et al. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem Biophys Res Commun 1997;240:391-94
26. Guo Z, Shao L, Zheng L, et al. miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes. Proc Natl Acad Sci U S A 2012;109:5826-31
27. Hoos MD, Richardson BM, Foster MW, et al. Longitudinal study of differential protein expression in an Alzheimers mouse model lacking inducible nitric oxide synthase. J Proteome Res 2013;12:4462-77
28. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482-97
29. Alamed J, Wilcock DM, Diamond DM, et al. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 2006;1:1671-79
30. Comery TA, Martone RL, Aschmies S, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimers disease. J Neurosci 2005;25:8898-902
31. Attems J, Yamaguchi H, Saido TC, et al. Capillary CAA and perivascular Abeta-deposition: Two distinct features of Alzheimers disease pathology. J Neurol Sci 2010;299:155-62
32. Biernat J, Mandelkow EM, Schroter C, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serineproline motifs upstream of the microtubule binding region. EMBO J 1992; 11:1593-97
33. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 2008;12:38-55
34. Lee JH, Goedert M, Hill WD, et al. Tau proteins are abnormally expressed in olfactory epithelium of Alzheimer patients and developmentally regulated in human fetal spinal cord. Exp Neurol 1993;121: 93-105
35. Steinhilb ML, Dias-Santagata D, Fulga TA, et al. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007;18:5060-68
36. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007;25:59-68
37. Seino Y, Kawarabayashi T, Wakasaya Y, et al. Amyloid beta accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. J Neurosci Res 2010;88:3547-54
38. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer diseaseYlike pathology. Proc Natl Acad Sci U S A 1997;94:13287-92
39. Tomidokoro Y, Ishiguro K, Harigaya Y, et al. Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett 2001;299:169-72
40. Merino-Serrais P, Benavides-Piccione R, Blazquez-Llorca L, et al. The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimers disease. Brain 2013;136:1913-28
41. Schneider A, Araujo GW, Trajkovic K, et al. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J Biol Chem 2004;279:55833-39
42. Planel E, Yasutake K, Fujita SC, et al. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001; 276:34298-306
43. Kampers T, Pangalos M, Geerts H, et al. Assembly of paired helical filaments from mouse tau: Implications for the neurofibrillary pathology in transgenic mouse models for Alzheimers disease. FEBS Lett 1999; 451:39-44
44. Graff-Radford J, Kantarci K. Magnetic resonance spectroscopy in Alzheimers disease. Neuropsychiatr Dis Treat 2013;9:687-96
45. Kantarci K. Magnetic resonance spectroscopy in common dementias. Neuroimaging Clin N Am 2013;23:393-406
46. Kantarci K. Proton MRS in mild cognitive impairment. J Magn Reson Imaging 2013;37:770-77
47. Kantarci K, Weigand SD, Przybelski SA, et al. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 2013;81:126-33
48. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56:592-98
49. Kantarci K, Petersen RC, Przybelski SA, et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008; 65:1621-28
50. Shinno H, Inagaki T, Miyaoka T, et al. A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimers disease. J Neurol Sci 2007;260:132-38
51. Tumati S, Martens S, Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis. Neurosci Biobehav Rev 2013;37:2571-86
52. Wolf HK, Buslei R, Schmidt-Kastner R, et al. NeuN: A useful neuronal marker for diagnostic histopathology. J Histochem Cytochem 1996;44: 1167-71
53. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010;65:7-19
54. Gallagher M, Koh MT. Episodic memory on the path to Alzheimers disease. Curr Opin Neurobiol 2011;21:929-34
55. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2: a006171
56. Palmer A, GoodM. Hippocampal synaptic activity, pattern separation and episodic-like memory: Implications for mouse models of Alzheimers disease pathology. Biochem Soc Trans 2011;39:902-9
57. Stewart S, Cacucci F, Lever C. Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimers mouse model. J Alzheimers Dis 2011;26:105-26
58. Shukitt-Hale B, McEwen JJ, Szprengiel A, et al. Effect of age on the radial arm water mazeVa test of spatial learning and memory. Neurobiol Aging 2004;25:223-29
59. Hunsaker MR. The importance of considering all attributes of memory in behavioral endophenotyping of mouse models of genetic disease. Behav Neurosci 2012;126:371-80
60. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274:99-102
61. Casas C, Sergeant N, Itier JM, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 2004;165:1289-300
62. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimers disease mutations: Potential factors in amyloid plaque formation. J Neurosci 2006;26:10129-40
63. Robbins EM, Betensky RA, Domnitz SB, et al. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci 2006;26:365-71
64. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, et al. The cerebral beta-amyloid angiopathies: Hereditary and sporadic. Brain Pathol 2006;16:30-39
65. Richard E, Carrano A, Hoozemans JJ, et al. Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2010; 69:1158-67
66. Attems J, Jellinger KA. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathologyVa pilot study. Acta Neuropathol 2004;107:83-90
67. Weller RO, Djuanda E, Yow HY, et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009;117:1-14
68. Wilcock DM, Vitek MP, Colton CA. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimers disease. Neuroscience 2009;159:1055-69
69. Reilly JF, Games D, Rydel RE, et al. Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A 2003;100:4837-42
70. Irizarry MC, Soriano F, McNamara M, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-59
71. Schmitz C, Rutten BP, Pielen A, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimers disease. Am J Pathol 2004;164:1495-502
72. Oshima K, Uchikado H, Dickson DW. Perivascular neuritic dystrophy associated with cerebral amyloid angiopathy in Alzheimers disease. Int J Clin Exp Pathol 2008;1:403-8
73. Van Nostrand WE, Xu F, Rozemuller AJ, et al. Enhanced capillary amyloid angiopathyYassociated pathology in Tg-SwDI mice with deleted nitric oxide synthase 2. Stroke 2010;41:S135-38
74. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11:909-13
75. Clavaguera F, Grueninger F, Tolnay M. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Neuropharmacology 2014;76:9-15
76. Iba M, Guo JL, McBride JD, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimers-like tauopathy. J Neurosci 2013;33:1024-37
77. Wu JW, Herman M, Liu L, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 2013;288:1856-70
78. Schonheit B, Zarski R, Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 2004;25:697-711
79. Yilmazer-Hanke DM, Hanke J. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation. Dement Geriatr Cogn Disord 1999;10:70-76
80. Adachi M, Kawakatsu S, Hosoya T, et al. Morphology of the inner structure of the hippocampal formation in Alzheimer disease. AJNR Am J Neuroradiol 2003;24:1575-81
81. Avila J. Tau phosphorylation and aggregation in Alzheimers disease pathology. FEBS Lett 2006;580:2922-27
82. Gertz HJ, Xuereb J, Huppert F, et al. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimers disease. Acta Neuropathol 1998;95:154-58
83. Giannakopoulos P, von Gunten A, Kovari E, et al. Stereological analysis of neuropil threads in the hippocampal formation: Relationships with Alzheimers disease neuronal pathology and cognition. Neuropathol Appl Neurobiol 2007;33:334-43
84. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-69
85. Lace G, Savva GM, Forster G, et al. Hippocampal tau pathology is related to neuroanatomical connections: An ageing populationYbased study. Brain 2009;132:1324-34
86. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimers disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
87. Ashe KH, Zahs KR. Probing the biology of Alzheimers disease in mice. Neuron 2010;66:631-45
88. Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 2004;188:52-64
89. LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:1-13
90. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
91. Blazquez-Llorca L, Garcia-Marin V, Merino-Serrais P, et al. Abnormal tau phosphorylation in the thorny excrescences of CA3 hippocampal neurons in patients with Alzheimers disease. J Alzheimers Dis 2011;26: 683-98
92. Adams SJ, Crook RJ, Deture M, et al. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am J Pathol 2009;175:1598-609
93. West MJ, Kawas CH, Stewart WF, et al. Hippocampal neurons in pre-clinical Alzheimers disease. Neurobiol Aging 2004;25:1205-12
94. Fernandez-Fernandez S, Almeida A, Bolanos JP. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J 2012; 443:3-11
95. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012; 1822:625-30
96. Oberg J, Spenger C, Wang FH, et al. Age related changes in brain metabolites observed by H MRS in APP/PS1 mice. Neurobiol Aging 2008;29:1423-33
97. Cheng LL, Newell K, Mallory AE, et al. Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 2002;20:527-33.
98. Haberman RP, Colantuoni C, Stocker AM, et al. Prominent hippocampal CA3 gene expression profile in neurocognitive aging. Neurobiol Aging 2011;32:1678-92
99. Hanseeuw BJ, Van Leemput K, Kavec M, et al. Mild cognitive impairment: Differential atrophy in the hippocampal subfields. AJNR Am J Neuroradiol 2011;32:1658-61
100. Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimers disease. Genes Brain Behav 2005;4:173-96
101. Liem RK, Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest 2009;119:1814-24
102. Ohama Y, Hayashi K. Relocalization of a microtubule-anchoring protein, ninein, from the centrosome to dendrites during differentiation of mouse neurons. Histochem Cell Biol 2009;132:515-24
103. Schoch S, Gundelfinger ED. Molecular organization of the presynaptic active zone. Cell Tissue Res 2006;326:379-91
104. Nithianantharajah J, Komiyama NH, McKechanie A, et al. Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nat Neurosci 2013;16:16-24
105. Bast T. Toward an integrative perspective on hippocampal function: From the rapid encoding of experience to adaptive behavior. Rev Neurosci 2007;18:253-81
106. Thompson CL, Pathak SD, Jeromin A, et al. Genomic anatomy of the hippocampus. Neuron 2008;60:1010-21
107. Wink DA, Hines HB, Cheng RY, et al. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011;89:873-91.
108. Reyes JF, Fu Y, Vana L, et al. Tyrosine nitration within the proline-rich region of Tau in Alzheimers disease. Am J Pathol 2011;178:2275-85
109. Vana L, Kanaan NM, Hakala K, et al. Peroxynitrite-induced nitrative and oxidative modifications alter tau filament formation. Biochemistry 2011;50:1203-12
110. Wahlund LO, Julin P, Johansson SE, et al. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: A comparative study. J Neurol Neurosurg Psychiatry 2000;69:630-35
111. Bresciani L, Rossi R, Testa C, et al. Visual assessment of medial temporal atrophy on MR films in Alzheimers disease: Comparison with volumetry. Aging Clin Exp Res 2005;17:8-13
112. Apostolova LG, Mosconi L, Thompson PM, et al. Subregional hippocampal atrophy predicts Alzheimers dementia in the cognitively normal. Neurobiol Aging 2010;31:1077-88